<i id='B4FF408927'><strike id='B4FF408927'><tt id='B4FF408927'><pre id='B4FF408927'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections 
Genentech weighs delaying cancer therapy after drug pricing law 
Activists slam private health insurers over coverage restrictions 
Target recalls 2.2 million additional candles due to laceration, burn hazards 
Medical leaders decry Supreme Court decision on affirmative action 
Novo acquires Inversago for up to $1 billion 
Psychedelics group wrestles with new pharma identity 
NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death 
Medical records are filled with copy 
After John Oliver segment, STAT readers share their opioid 
BioMarin wins approval for gene therapy to treat hemophilia A 
Maui funeral service workers on devastation of fires: 'I'm in shock' 
ChatGPT in medicine: STAT answers readers' burning questions 
Positive childhood experiences can help future health
Medical records are filled with copy 
